Rogers Corp. Dl 1 Stock
Price
Target price
?
?
-0.870%
-1.0
-0.870%
-
08:10 / Frankfurt
WKN: 863178 / Name: Roger / Stock / Semiconductors & Semiconductor Equipment / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Rogers Corp. Dl 1 Stock
Rogers Corp. Dl 1 shows a slight decrease today, losing -€1.000 (-0.870%) compared to yesterday.
So far the community has only identified positive things for Rogers Corp. Dl 1 stock. The most positive votes were given for criterium "Non-cyclic/Cyclic".
Pros and Cons of Rogers Corp. Dl 1 in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
B****
?
G***** c******* t* c**********
Cons
?
C******** o* t** e**********
?
S********** s********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Rogers Corp. Dl 1 vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Rogers Corp. Dl 1 | -0.870% | 3.810% | -12.800% | 81.667% | 37.975% | -20.727% | -31.875% |
| Vishay Intertechnology Inc. | 5.310% | 17.340% | -16.646% | 140.800% | 166.088% | 35.887% | 80.214% |
| Universal Display Corp. | -0.430% | 3.486% | 6.949% | -39.580% | -26.523% | -47.983% | -61.264% |
| Silicon Labs Inc. | -1.060% | -0.532% | 0.000% | 64.035% | 68.468% | 48.413% | 41.667% |
News
iRadimed Q2 Earnings Call Highlights
Key Points
- Interested in iRadimed Corporation? Here are five stocks we like better.
- iRadimed’s new 3870 pump is seeing strong demand: Second-quarter bookings exceeded shipments by more than
Avalyn Pharma Outlines Inhaled Fibrosis Push After IPO, With Pivotal Data Ahead
Key Points
- Interested in Avalyn Pharma Inc.? Here are five stocks we like better.
- Avalyn Pharma is pursuing inhaled versions of approved pulmonary fibrosis drugs to reduce side effects that
IRADIMED's CEO Is Selling Steadily — The Plan, Not the Stock, Is Driving It
Roger E. Susi, CEO, President, and Chairman of IRADIMED CORPORATION (NASDAQ:IRMD), reported the indirect sale of 7,500 shares of common stock across multiple open-market transactions on May 26, 2026
